Form 4: Biofrontera AG Boosts Stake in Biofrontera Inc.

Biofrontera AG, a 10% owner and director, acquired 3,019 Series D Convertible Preferred Stock in Biofrontera Inc. through an asset exchange.

Summary

• Biofrontera AG, a director and 10% owner of Biofrontera Inc., acquired 3,019 shares of Series D Convertible Preferred Stock.
• The acquisition occurred on September 16, 2025, through a privately negotiated transaction.
• The preferred stock was exchanged for assets related to the production and sale of certain products in the United States, with an estimated market value of approximately $3,019,000.
• Each share of Series D Convertible Preferred Stock is convertible at any time into common stock at the holder's election, with no expiration date.
• The conversion price for the derivative security is $0.0006 per common share.
• Following the transaction, Biofrontera AG beneficially owns 3,019 Series D Convertible Preferred Stock, which underlies 4,831,172 shares of common stock.
• Biofrontera AG has the right to appoint one representative to the board of directors of Biofrontera Inc., with Dr. Heikki Lanckriet currently serving in this capacity.

Sentiment

Score: 7

Explanation: The acquisition of additional equity by a significant shareholder and director, in exchange for operational assets, generally indicates confidence in the company's future and strengthens its asset base.

Positives

• A significant shareholder and director, Biofrontera AG, is increasing its equity stake in Biofrontera Inc., signaling confidence in the company's future.
• The transaction involves the exchange of assets related to product production and sale, which could enhance Biofrontera Inc.'s operational capabilities and asset base.
• The Series D Convertible Preferred Stock has no expiration date and is convertible at any time, providing flexibility to the holder.

Future Outlook

NA

Management Comments

• The Reporting Person has entered into an agreement with the Issuer pursuant to which the Reporting Person may appoint one representative to the board of directors of the Issuer.
• Dr. Heikki Lanckriet has been deputized to represent the Reporting Person on the board of directors of the Issuer.
• By virtue of Dr. Lanckriet's representation, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed a director by deputization of the Issuer.

Industry Context

This filing reports an insider transaction, which is specific to the relationship between Biofrontera AG and Biofrontera Inc. and does not directly provide broader industry trends or competitive analysis.

Management Changes

Corporate Governance

Related Party Transactions

• The acquisition of Series D Convertible Preferred Stock by Biofrontera AG (a 10% owner and director) from Biofrontera Inc. in exchange for assets constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Increased ownership by a major shareholder could be seen as a positive signal of confidence. The asset exchange could benefit the company's operations.
• Management: The deputization of Dr. Heikki Lanckriet reinforces Biofrontera AG's influence on the board.

Key Dates

Keywords

Biofrontera AG, Biofrontera Inc., BFRI, Form 4, Insider Transaction, Convertible Preferred Stock, Asset Exchange, Beneficial Ownership, Director Appointment